These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35349370)

  • 1. Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience.
    Maron SB; Moya S; Morano F; Emmett MJ; Chou JF; Sabwa S; Walch H; Peterson B; Schrock AB; Zhang L; Janjigian YY; Chalasani S; Ku GY; Disel U; Enzinger P; Uboha N; Kato S; Yoshino T; Shitara K; Nakamura Y; Saeed A; Kasi PM; Chao J; Lee J; Capanu M; Wainberg Z; Petty R; Pietrantonio F; Klempner SJ; Catenacci DVT
    J Clin Oncol; 2022 Aug; 40(22):2458-2467. PubMed ID: 35349370
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Zhang L; Hamdani O; Gjoerup O; Cho-Phan C; Snider J; Castellanos E; Nimeiri H; Frampton G; Venstrom JM; Oxnard G; Klempner SJ; Schrock AB
    JCO Precis Oncol; 2022 Jan; 6():e2100330. PubMed ID: 35050711
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Klempner SJ; Madison R; Pujara V; Ross JS; Miller VA; Ali SM; Schrock AB; Kim ST; Maron SB; Dayyani F; Catenacci DVT; Lee J; Chao J
    Oncologist; 2019 Nov; 24(11):1462-1468. PubMed ID: 31249137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.
    Lennerz JK; Kwak EL; Ackerman A; Michael M; Fox SB; Bergethon K; Lauwers GY; Christensen JG; Wilner KD; Haber DA; Salgia R; Bang YJ; Clark JW; Solomon BJ; Iafrate AJ
    J Clin Oncol; 2011 Dec; 29(36):4803-10. PubMed ID: 22042947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
    Lorenzen S; Riera Knorrenschild J; Haag GM; Pohl M; Thuss-Patience P; Bassermann F; Helbig U; Weißinger F; Schnoy E; Becker K; Stocker G; Rüschoff J; Eisenmenger A; Karapanagiotou-Schenkel I; Lordick F
    Eur J Cancer; 2015 Mar; 51(5):569-76. PubMed ID: 25694417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
    Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
    Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma.
    Maron SB; Chase LM; Lomnicki S; Kochanny S; Moore KL; Joshi SS; Landron S; Johnson J; Kiedrowski LA; Nagy RJ; Lanman RB; Kim ST; Lee J; Catenacci DVT
    Clin Cancer Res; 2019 Dec; 25(23):7098-7112. PubMed ID: 31427281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Back from the Brink: EGFR Inhibition in Gastroesophageal Cancer.
    Openshaw MR; Pinato DJ; Valeri N
    Clin Cancer Res; 2021 Jun; 27(11):2964-2966. PubMed ID: 33771852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.
    Hecht JR; Bang YJ; Qin SK; Chung HC; Xu JM; Park JO; Jeziorski K; Shparyk Y; Hoff PM; Sobrero A; Salman P; Li J; Protsenko SA; Wainberg ZA; Buyse M; Afenjar K; Houé V; Garcia A; Kaneko T; Huang Y; Khan-Wasti S; Santillana S; Press MF; Slamon D
    J Clin Oncol; 2016 Feb; 34(5):443-51. PubMed ID: 26628478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma.
    Gambardella V; Fleitas T; Tarazona N; Cejalvo JM; Gimeno-Valiente F; Martinez-Ciarpaglini C; Huerta M; Roselló S; Castillo J; Roda D; Cervantes A
    Ann Oncol; 2019 Aug; 30(8):1254-1264. PubMed ID: 31046106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress and challenges in HER2-positive gastroesophageal adenocarcinoma.
    Zhao D; Klempner SJ; Chao J
    J Hematol Oncol; 2019 May; 12(1):50. PubMed ID: 31101074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.
    Bartley AN; Washington MK; Ventura CB; Ismaila N; Colasacco C; Benson AB; Carrato A; Gulley ML; Jain D; Kakar S; Mackay HJ; Streutker C; Tang L; Troxell M; Ajani JA
    Am J Clin Pathol; 2016 Dec; 146(6):647-669. PubMed ID: 28077399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world treatment patterns and clinical outcomes for chemotherapy-based regimens in first-line MSI-H/dMMR metastatic colorectal cancer.
    Amonkar MM; Chase M; Myer NM; Wang T; Turzhitsky V; Spira A
    Cancer Treat Res Commun; 2023; 36():100712. PubMed ID: 37301728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients.
    Paul T; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Steffens M; Scholl C; Hichert V; Seufferlein T; Stingl JC
    Eur J Cancer; 2014 Jul; 50(11):1855-63. PubMed ID: 24857781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers.
    Smyth EC; Vlachogiannis G; Hedayat S; Harbery A; Hulkki-Wilson S; Salati M; Kouvelakis K; Fernandez-Mateos J; Cresswell GD; Fontana E; Seidlitz T; Peckitt C; Hahne JC; Lampis A; Begum R; Watkins D; Rao S; Starling N; Waddell T; Okines A; Crosby T; Mansoor W; Wadsley J; Middleton G; Fassan M; Wotherspoon A; Braconi C; Chau I; Vivanco I; Sottoriva A; Stange DE; Cunningham D; Valeri N
    Gut; 2021 Sep; 70(9):1632-1641. PubMed ID: 33199443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An investigation of the clinical impact and therapeutic relevance of a DNA damage immune response (DDIR) signature in patients with advanced gastroesophageal adenocarcinoma.
    Baxter MA; Spender LC; Cairns D; Walsh S; Oparka R; Porter RJ; Bray S; Skinner G; King S; Turbitt J; Collinson D; Miedzybrodzka ZH; Jellema G; Logan G; Kennedy RD; Turkington RC; McLean MH; Swinson D; Grabsch HI; Lord S; Seymour MJ; Hall PS; Petty RD
    ESMO Open; 2024 May; 9(5):103450. PubMed ID: 38744099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Spatial Heterogeneity Within Nonmetastatic Gastroesophageal Adenocarcinomas and Survival.
    Chao J; Bedell V; Lee J; Li MS; Chu P; Yuan YC; Zhao D; Klempner SJ; Lin RJ
    JAMA Netw Open; 2020 Apr; 3(4):e203652. PubMed ID: 32338752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial.
    Malka D; François E; Penault-Llorca F; Castan F; Bouché O; Bennouna J; Ghiringhelli F; de la Fouchardière C; Borg C; Samalin E; Bachet JB; Raoul JL; Miglianico L; Bengrine-Lefèvre L; Dahan L; Lecaille C; Aparicio T; Stanbury T; Perrier H; Cayre A; Laurent-Puig P; Gourgou S; Emile JF; Taïeb J
    Eur J Cancer; 2019 Jul; 115():97-106. PubMed ID: 31129386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between timely targeted treatment and outcomes in patients with metastatic HER2-overexpressing gastroesophageal adenocarcinoma.
    Lau-Min KS; Li Y; Eads JR; Mamtani R; Getz KD
    Cancer; 2022 May; 128(9):1853-1862. PubMed ID: 35119688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort.
    Apicella M; Migliore C; Capelôa T; Menegon S; Cargnelutti M; Degiuli M; Sapino A; Sottile A; Sarotto I; Casorzo L; Cassoni P; De Simone M; Comoglio PM; Marsoni S; Corso S; Giordano S
    Oncogene; 2017 Mar; 36(9):1200-1210. PubMed ID: 27524418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.